Approval · Notice of Compliance 16503 · 2015
TEVETEN PLUS: Notice of Compliance 16503
Issued January 7, 2015
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 16503
- Date
- January 7, 2015
- Company
- BGP Pharma ULCEtobicoke, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Transfer of drug identification number
- Therapeutic class
- Angiotensin II receptor (at1) antagonist and diuretic
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TEVETEN PLUS | 02253631 | Cancelled Post Market |
Medicinal ingredients
- HYDROCHLOROTHIAZIDE 12.5 MG per TAB
- EPROSARTAN MESYLATE 600 MG per TAB